9781630913212

Anti-vegf Use in Ophthalmology

by ;
  • ISBN13:

    9781630913212

  • ISBN10:

    1630913219

  • Edition: 1st
  • Format: Paperback
  • Copyright: 2017-05-15
  • Publisher: Slack Incorporated

Note: Supplemental materials are not guaranteed with Rental or Used book purchases.

Purchase Benefits

  • Free Shipping On Orders Over $35!
    Your order must be $35 or more to qualify for free economy shipping. Bulk sales, PO's, Marketplace items, eBooks and apparel do not qualify for this offer.
  • Get Rewarded for Ordering Your Textbooks! Enroll Now
List Price: $106.61 Save up to $42.64
  • Rent Book $63.97
    Add to Cart Free Shipping

    TERM
    PRICE
    DUE
    IN STOCK USUALLY SHIPS IN 24 HOURS

Supplemental Materials

What is included with this book?

  • The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
  • The Rental copy of this book is not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.

Summary

The introduction of anti-vascular endothelial growth factor (VEGF) agents has revolutionized therapy for a host of ocular diseases associated with leakage from normal blood vessels and pathologic blood vessel growth. Anti-VEGF Use in Ophthalmology is an all-inclusive reference designed to provide detailed, up-to-date, and clinically relevant information on the current use of anti-VEGF agents in the treatment of all ocular conditions.

Drs. Jay S. Duker and Michelle C. Liang have assembled a prestigious group of contributors who pool their collective expertise in this comprehensive book. Anti-VEGF Use in Ophthalmology is split into two sections with the first providing the history of VEGF and an overview of anti-VEGF agents and different routes of drug delivery, as it is important for eye care providers to be familiar with up-to-date aspects of the medications and indications for use.

The second section details the clinical uses of anti-VEGF agents in numerous ocular diseases, from the anterior segment including cornea and glaucoma to uveitis and various retinal and choroidal diseases. Each chapter in this section summarizes the disease process and utilizes high-quality ocular imaging to demonstrate the therapeutic use of the anti-VEGF agents.

Some of the topics covered in Anti-VEGF Use in Ophthalmology:
  • Neovascular Age-Related Macular Degeneration
  • Proliferative Diabetic Retinopathy
  • Retinal Vein Occlusion
  • Uveitis
  • Neovascular Glaucoma
  • Macular Edema
  • Retinopathy of Prematurity
  • Corneal Disease
Anti-VEGF Use in Ophthalmology combines the theory and applications of anti-VEGF agents, making it not only a great learning tool for beginners but also a useful reference tool for a wide range of eye care professionals including optometrists, residents, comprehensive ophthalmologists, as well as specialists in anterior segment, pediatrics, and vitreoretinal disease.
 

Author Biography

Jay S. Duker, MD, is Professor and Chairman of Ophthalmology at the Tufts Medical Center and Tufts University School of Medicine and Director of the New England Eye Center in Boston, Massachusetts. Dr. Duker graduated from Jefferson Medical College and completed ophthalmology and retina training at the Wills Eye Hospital. His research and clinical interests are focused on the posterior segment ranging from macular degeneration, diabetic retinopathy, and retinal vascular diseases, as well as uveitis and intraocular tumors. He has published more than 280 journal articles and has been lead editor on six books and dozens of book chapters. Dr. Duker is the co-editor of the International Journal of Retina and Vitreous.
 
Michelle C. Liang, MD, is Assistant Professor of Ophthalmology at the Tufts University School of Medicine and a vitreoretinal specialist at the New England Eye Center in Boston, Massachusetts. She graduated with honors from Johns Hopkins University with a degree in Biology and earned her medical degree from the University at Buffalo School of Medicine and Biomedical Sciences. She performed her residency in ophthalmology at the New England Eye Center at Tufts Medical Center and went on to complete a vitreoretinal surgery fellowship at the New England Eye Center and Ophthalmic Consultants of Boston.
Dr. Liang has authored numerous scientific papers and book chapters and has presented at several national meetings. She treats all conditions of the retina and vitreous, including macular degeneration, vitreomacular disorders, diabetic retinopathy, retinal vascular disorders, retinal detachment, and cataract complications. Her research interests include retinal imaging and new therapies for macular degeneration, diabetic macular edema, and other diseases. Dr. Liang is a board-certified member of the American Board of Ophthalmology and a member of the American Academy of Ophthalmology and American Society of Retinal Specialists.
 

Table of Contents

Dedication

About the Editors

Contributing Authors

Introduction

Section I        Overview of Anti-Vascular Endothelial
                          Growth Factor Agents

Chapter 1         Vascular Endothelial Growth Factor:
                          Background and History

Anthony Joseph, MD and Ehsan Rahimy, MD

Chapter 2         Development of Anti-Vascular Endothelial
                          Growth Factor Agents

Maya H. Maloney, MD and Sophie J. Bakri, MD

Chapter 3         Available Anti-Vascular Endothelial
                          Growth Factor Agents

Angeline Mariani Derham, MD and David M. Brown, MD, FACS

Chapter 4         Agents Under Study

                          Ehsan Rahimy, MD; Elham Rahimy, BS;
                          and Anthony Joseph, MD

Chapter 5         Intravitreal Delivery

Nora Muakkassa, MD; Kendra Klein, MD; and
Elias Reichel, MD

Chapter 6         Sustained Delivery Options Under Study

Michael N. Cohen, MD; Chirag P. Shah, MD, MPH; and
Jeffrey S. Heier, MD

Section II      Use of Anti-Vascular Endothelial
                          Growth Factor Agents in Clinical Practice

Chapter 7         Neovascular Age-Related Macular Degeneration

Michael D. Lewen, MD and Andre J. Witkin, MD

Chapter 8         Choroidal Neovascularization,
                          Not Age-Related Macular Degeneration

Darin R. Goldman, MD

Chapter 9         Diabetic Macular Edema

Emily D. Cole, BS; Eduardo A. Novais MD; and
Nadia K. Waheed, MD, MPH

Chapter 10       Proliferative Diabetic Retinopathy

Sabin Dang, MD and Chirag P. Shah, MD, MPH

Chapter 11       Retinal Vein Occlusion

Shilpa Desai, MD and Caroline R. Baumal, MD

Chapter 12       Uveitis

Lana M. Rifkin, MD

Chapter 13       Retinopathy of Prematurity

Nikisha A. Kothari, MD and Audina M. Berrocal, MD

Chapter 14       Miscellaneous Retinal and Choroidal Diseases

Michael D. Tibbetts, MD

Chapter 15       Neovascular Glaucoma

Manik Goel, MD and Joel S. Schuman, MD, FACS

Chapter 16       Glaucoma Surgery

Jessica J. Moon, MD and Cynthia Mattox, MD

Chapter 17       Anterior Segment Diseases

Alessandro Abbouda, MD; Bijan Khaksari, BA; and
Pedram Hamrah, MD, FRCS

Financial Disclosures

Index

Rewards Program

Write a Review